4//SEC Filing
Evoke Pharma Inc 4
Accession 0000904454-16-001170
$EVOKCIK 0001403708operating
Filed
Apr 20, 8:00 PM ET
Accepted
Apr 21, 4:57 PM ET
Size
15.4 KB
Accession
0000904454-16-001170
Insider Transaction Report
Form 4
Evoke Pharma IncEVOK
TREU JESSE I
10% Owner
Transactions
- Sale
Common Stock
2016-04-20$5.29/sh−4,424$23,403→ 955,498 total - Sale
Common Stock
2016-04-19$5.36/sh−37,054$198,609→ 959,922 total
VITULLO NICOLE
10% Owner
Transactions
- Sale
Common Stock
2016-04-19$5.36/sh−37,054$198,609→ 959,922 total - Sale
Common Stock
2016-04-20$5.29/sh−4,424$23,403→ 955,498 total
BLAIR JAMES C
10% Owner
Transactions
- Sale
Common Stock
2016-04-19$5.36/sh−37,054$198,609→ 959,922 total - Sale
Common Stock
2016-04-20$5.29/sh−4,424$23,403→ 955,498 total
DOVEY BRIAN H
10% Owner
Transactions
- Sale
Common Stock
2016-04-20$5.29/sh−4,424$23,403→ 955,498 total - Sale
Common Stock
2016-04-19$5.36/sh−37,054$198,609→ 959,922 total
Halak Brian K
10% Owner
Transactions
- Sale
Common Stock
2016-04-19$5.36/sh−37,054$198,609→ 959,922 total - Sale
Common Stock
2016-04-20$5.29/sh−4,424$23,403→ 955,498 total
DOMAIN PARTERS VII L P
10% Owner
Transactions
- Sale
Common Stock
2016-04-19$5.36/sh−37,054$198,609→ 959,922 total - Sale
Common Stock
2016-04-20$5.29/sh−4,424$23,403→ 955,498 total
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.20 to $5.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F2]The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VII, LLC ("OPSA VII"), the sole general partner of the Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- [F3]As managing members of OPSA VII, which is also the sole general partner of DP VII Associates, L.P. each Reporting Owner listed below may also be deemed to indirectly beneficially own 16,290 shares of Common Stock held by DP VII Associates, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by DP VII Associates, L.P., however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- [F4]As managing members of Domain Associates, LLC, each Reporting Owner listed below may also be deemed to indirectly beneficially own 5,250 shares of Common Stock held by Domain Associates, LLC. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by Domain Associates, LLC, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.20 to $5.36. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Documents
Issuer
Evoke Pharma Inc
CIK 0001403708
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001403708
Filing Metadata
- Form type
- 4
- Filed
- Apr 20, 8:00 PM ET
- Accepted
- Apr 21, 4:57 PM ET
- Size
- 15.4 KB